statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NLS Pharmaceutics (NASDAQ:NLSP - Get Free Report) and G1 Therapeutics (NASDAQ:GTHX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses...

Head to Head Review: NLS Pharmaceutics (NASDAQ:NLSP) versus G1 Therapeutics (NASDAQ:GTHX)

NLS Pharmaceutics Ltd. (NASDAQ:NLSP  Get Free Report) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 35,200 shares, a drop of...

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Sees Significant Drop in Short Interest

ZURICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ('NLS' or the 'Company'), a Swiss clinical-stage biopharmaceutical company focused on the...

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in...

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

NLS Pharmaceutics announces $1.75M registered direct offering

ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ('NLS' or the 'Company'), a Swiss clinical-stage biopharmaceutical company focused on the...

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ('NLS' or the 'Company'), a Swiss clinical-stage biopharmaceutical company focused on the...

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

NLS Pharmaceutics announces Nasdaq acceptance of plan to regain compliance

ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ('NLS' or the 'Company'), a Swiss clinical-stage biopharmaceutical company focused on the...

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

NLS Pharmaceutics submits plan to regain Nasdaq listing compliance

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

Watchers	4,721
52-Wk Low	$0.113
52-Wk High	$1.53

Volume	36,940.00
52-Wk High	$1.53
52-Wk Low	$0.113

NLSP NLS Pharmaceutics Ltd

About

Feed

News

Fundamentals